By Lorinda G. Holloway and Timothy P. Ribelin
The federal government contributed over $40 billion to university-related research and development projects in 2017. Academic institutions―most often colleges, universities, and related hospitals―rely on these grants to fund research, support faculty and staff, train students, create collaboration opportunities, and enhance facilities and equipment. However, federal research grants create at least two areas of False Claims Act exposure for academic institutions—proper use of the funds and research misconduct. Indeed, a recent False Claims Act settlement for $112.5 million is a jolting reminder that institutions must promptly address (and sequester) alleged research misconduct.
Identifying Research Misconduct
The scientific method demands that scientists scrutinize their data and determine if it supports their original hypotheses. If not, scientists must perform additional research, testing, and analysis while modifying their original hypotheses.
The economic pressures of research funding often counterbalance scientific endeavors. Government-funded research dollars are vital to the success and prestige of academic institutions. Professional advancement for research faculty members often requires obtaining grants to fund their research and publishing the results. Yet, competition for these research funds is high.
Research misconduct occurs when researchers―consciously or otherwise―place professional advancement above the rigors of the scientific method. Faced with allegations of research misconduct, the investigating body must promptly and thoroughly investigate the allegations, while also taking care to prevent unnecessarily tarnishing the researcher’s reputation.
Missing the mark on these obligations exposes the academic institution to False Claims Act liability. The recent United States ex rel. Thomas v. Duke Univ., et al. case drew considerable attention not only because of the $112M settlement amount, but also because the focus was the alleged mishandling of the investigation. This complaint alleged Duke discovered pervasive research misconduct in one lab and then, according to the relator, knowingly submitted 30 grants to the National Institute of Health (NIH) and Environmental Protection Agency (EPA) that contained the falsified or fabricated data, perpetuating the research misconduct rather than containing and disclosing it.
Assuring Compliance through the Integrity Rules
Federal regulations “establish[ed] uniform policies and procedures for investigating and reporting instances of alleged or apparent misconduct involving research or research training, application for support of research or research training, or related activities that are supported with funds made available under the [Public Health Service] Act.”
In addition to the research grant dollars, academic institutions receive additional funds to pay for the “indirect costs” associated with administering grants. Through these indirect costs, the Public Health Service Act regulations impose an affirmative duty to ensure the integrity of the research programs. This can be accomplished only through a robust compliance program that examines how research dollars are acquired and spent, and scrutinizes both the research and the research process itself. When any component lacks integrity, the institution must consider self-disclosure or risk suffering damaging results.
A necessary component of any academic institution’s compliance program is a detailed plan to handle allegations of research misconduct. The academic institution must provide assurances it has complied with the Public Services Act (and appropriate regulations) that require, in part:
- immediate and appropriate action upon receiving allegations of research misconduct;
- policies and procedures setting forth the protocol for investigating these allegations;
- notifying the Office of Scientific Integrity of reporting requirements; and
- if necessary, promptly conducting an investigation.
The internal investigation will likely play a key role in determining (or at least mitigating) potential exposure under the False Claims Act.
Preventing and Mitigating FCA Claims ‒ Impactful Response
In 1863, Congress designed a system to detect and reduce fraud against the government. Today, the False Claims Act encourages individuals with knowledge of suspected government fraud to file qui tam lawsuits against institutions and individuals that have benefitted from the alleged fraudulent conduct. Research misconduct involving federally-funded research grants can lead to a qui tam lawsuit for violating the False Claims Act. Plaintiffs (or relators) file qui tam actions against academic institutions for scientific misconduct involving allegations of, among other things, supporting grant applications with fabricated data.
In the Duke case, the relator alleged that a clinical research coordinator in the school’s Airway Physiology Laboratory operated several machines that provided key data to experiments involving pulmonary research studies on mice. The relator alleged that the research coordinator “committed research misconduct and fraud on nearly every experiment or project with which she was involved.” The allegations of research misconduct ranged from making up data to running the experiments but altering the data so it conformed to the original hypothesis.
In March 2013, Duke allegedly reviewed the experiments described above and discovered this fraudulent data. The complaint alleges that Duke and others concealed “research misconduct, rather than make complete and timely disclosures,” delayed retracting publications premised on fraudulent data, and submitted additional grants and progress reports after Duke discovered the false or fabricated data. According to the relators’ attorneys, one of his motivations for pursuing this lawsuit was Duke’s alleged lack of transparency after discovering the false data.
This fact pattern is not unique in research misconduct False Claims Act cases. The plaintiff (or relator) often files at least one complaint with the academic institution’s administration. Institutions should seize this opportunity to understand the allegations and potentially prevent a False Claims Act investigation. Though federal regulations define the investigation process, institutions must understand the broader implications of these allegations and prevent making additional certifications or representations based on the research until the institution has fully vetted the allegations. Failing to do so quickly and carefully increases the likelihood that the institution is incurring liability through additional false claims.
Research misconduct threatens the integrity of the scientific process and colleges, universities, and hospitals in which it resides. Robust compliance programs help ensure that professors, staff, and students understand research misconduct and the implications thereof. Training, however, is not enough. An academic institution faced with allegations of research misconduct must quickly investigate. In addition, it must sequester projects within the scope of the research misconduct to mitigate (or prevent) any additional liability under the False Claims Act. Until the academic institution understands the merit of the allegations involving research misconduct (if any), it must take great care to prevent the problem from growing.
Lorinda Holloway is the Office Managing Partner of Husch Blackwell LLP’s Austin, Texas, office. Her practice focuses on advising and defending healthcare and educational institutions involved in government investigations and False Claims Act lawsuits. Timothy Ribelin is an Austin-based associate with Husch Blackwell LLP who is involved all aspects of commercial litigation for healthcare and financial service-related clients, including defending clients involved in government investigations and False Claims Act lawsuits. Before attending law school, Timothy earned his M.S. in Medicinal Chemistry from the University of Kansas and worked as a research scientist for 5 years in the pharmaceutical industry.
Healthcare Business Today is a leading online publication that covers the business of healthcare. Our stories are written from those who are entrenched in this field and helping to shape the future of this industry. Healthcare Business Today offers readers access to fresh developments in health, medicine, science, and technology as well as the latest in patient news, with an emphasis on how these developments affect our lives.